Recruiting Endometrial Cancer Studies in Miami Beach
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that starts in the tissues ...
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or p...
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembroliz...
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurren...
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC)....
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent end...
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer...
About Endometrial Cancer Clinical Trials in Miami Beach
Endometrial cancer begins in the lining of the uterus and is the most common gynecologic cancer. It is often detected early due to abnormal bleeding symptoms. Treatment typically involves surgery, with radiation, chemotherapy, or hormone therapy for advanced cases.
There are currently 7 endometrial cancer clinical trials recruiting participants in Miami Beach, FL. These studies are seeking a combined 2,716 participants. Research is being sponsored by Merck Sharp & Dohme LLC, AstraZeneca, Alliance Foundation Trials, LLC. and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Endometrial Cancer Clinical Trials in Miami Beach — FAQ
Are there endometrial cancer clinical trials in Miami Beach?
Yes, there are 7 endometrial cancer clinical trials currently recruiting in Miami Beach, FL. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Miami Beach?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Miami Beach research site will contact you about next steps.
Are clinical trials in Miami Beach free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Miami Beach studies also compensate for your time and travel.
What endometrial cancer treatments are being tested?
The 7 active trials in Miami Beach are testing new therapies including novel drugs, biologics, and treatment approaches for endometrial cancer.
Data updated March 2, 2026 from ClinicalTrials.gov